Format

Send to

Choose Destination
J Med Chem. 2016 Feb 25;59(4):1580-98. doi: 10.1021/acs.jmedchem.5b01527. Epub 2015 Dec 23.

Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.

Author information

1
Structural Genomics Consortium, University of Oxford , Oxford OX3 7DQ, U.K.
2
Nuffield Department of Clinical Medicine, Target Discovery Institute (TDI), University of Oxford , Oxford OX3 7BN, U.K.
3
Botnar Research Center, University of Oxford , Oxford OX3 7LD, U.K.

Abstract

Development of tool molecules that inhibit Jumonji demethylases allows for the investigation of cancer-associated transcription. While scaffolds such as 2,4-pyridinedicarboxylic acid (2,4-PDCA) are potent inhibitors, they exhibit limited selectivity. To discover new inhibitors for the KDM4 demethylases, enzymes overexpressed in several cancers, we docked a library of 600,000 fragments into the high-resolution structure of KDM4A. Among the most interesting chemotypes were the 5-aminosalicylates, which docked in two distinct but overlapping orientations. Docking poses informed the design of covalently linked fragment compounds, which were further derivatized. This combined approach improved affinity by ∼ 3 log-orders to yield compound 35 (Ki = 43 nM). Several hybrid inhibitors were selective for KDM4C over the related enzymes FIH, KDM2A, and KDM6B while lacking selectivity against the KDM3 and KDM5 subfamilies. Cocrystal structures corroborated the docking predictions. This study extends the use of structure-based docking from fragment discovery to fragment linking optimization, yielding novel KDM4 inhibitors.

PMID:
26699912
PMCID:
PMC5080985
DOI:
10.1021/acs.jmedchem.5b01527
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center